Ashland Inc. logo

Ashland Inc. (ASH)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
71. 15
-0.44
-0.6146%
$
3.23B Market Cap
25.2 P/E Ratio
1.62% Div Yield
430,000 Volume
3.83 Eps
$ 71.59
Previous Close
Add Transaction
Day Range
70.99 73.05
Year Range
47.12 78.25
Want to track ASH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Ashland (ASH) Q3 Earnings and Revenues Miss Estimates

Ashland (ASH) Q3 Earnings and Revenues Miss Estimates

Ashland (ASH) came out with quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.49 per share a year ago.

Zacks | 1 year ago
Analysts Estimate Ashland (ASH) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Ashland (ASH) to Report a Decline in Earnings: What to Look Out for

Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Ashland Advances Strategic $60M Manufacturing Network Optimization

Ashland Advances Strategic $60M Manufacturing Network Optimization

ASH is closing two New Jersey sites as part of a $60M plan to boost efficiency, cut costs and scale key tech production.

Zacks | 1 year ago
Why Is Ashland (ASH) Up 3.9% Since Last Earnings Report?

Why Is Ashland (ASH) Up 3.9% Since Last Earnings Report?

Ashland (ASH) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Ashland's Q2 Earnings and Revenues Miss Estimates, Down Y/Y

Ashland's Q2 Earnings and Revenues Miss Estimates, Down Y/Y

ASH's fiscal second-quarter sales are adversely impacted by the portfolio optimization actions.

Zacks | 1 year ago
Ashland, Inc. (ASH) Q2 2025 Earnings Call Transcript

Ashland, Inc. (ASH) Q2 2025 Earnings Call Transcript

Ashland, Inc. (NYSE:ASH ) Q2 2025 Earnings Conference Call May 1, 2025 10:00 AM ET Company Participants William Whitaker - VP, Finance & Director, IR Guillermo Novo - Chairman & CEO John Willis - SVP, CFO & Principal Accounting Officer Alessandra Faccin - SVP and GM, Life Sciences and Intermediates James Minicucci - SVP & GM, Personal Care Dago Caceres - SVP & General Manager, Specialty Additives Conference Call Participants Kevin Estok - Jefferies Bhavesh Lodaya - BMO Capital Markets Jeff Zekauskas - JPMorgan David Begleiter - Deutsche Bank Josh Spector - UBS Michael Sison - Wells Fargo John Roberts - Mizuho Mike Harrison - Seaport Research Partners Operator Hello, and welcome to Ashland's Second Quarter Fiscal Year 2025 Earnings Conference Call and Webcast. [Operator Instructions] I would now like to turn the conference over to William Whitaker.

Seekingalpha | 1 year ago
Ashland (ASH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Ashland (ASH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Ashland (ASH) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 1 year ago
Ashland (ASH) Lags Q2 Earnings and Revenue Estimates

Ashland (ASH) Lags Q2 Earnings and Revenue Estimates

Ashland (ASH) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.27 per share a year ago.

Zacks | 1 year ago
Earnings Preview: Ashland (ASH) Q2 Earnings Expected to Decline

Earnings Preview: Ashland (ASH) Q2 Earnings Expected to Decline

Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Ashland Wraps Up Expansion of Pharmaceutical Plant in Brazil

Ashland Wraps Up Expansion of Pharmaceutical Plant in Brazil

ASH is investing in modernizing equipment for microbial protection in personal care applications at its Technical Center in Sao Paulo.

Zacks | 1 year ago
Ashland Wraps Up Divestment of Avoca Business to Mane

Ashland Wraps Up Divestment of Avoca Business to Mane

ASH closes the sales of its Avoca business, the last entity remaining from the Pharmachem acquisition.

Zacks | 1 year ago
Ashland Presents Attractive Upside Emerging From The Downcycle

Ashland Presents Attractive Upside Emerging From The Downcycle

Ashland is generating attractive free cash flow and is well-positioned to achieve its 2027 target of $600 million EBITDA and 50% FCF conversion rate. Despite the stock selling off over the last 8 months, Ashland's strategic acquisitions and divestitures have strengthened its market position, with a focus on high-margin, patent-protected products. Ashland's strong balance sheet, low leverage, and fixed-rate debt provide stability and flexibility to navigate the current downcycle in the specialty chemicals sector.

Seekingalpha | 1 year ago
Loading...
Load More